Latest News and Press Releases

LONDON, July 20, 2026 (GLOBE NEWSWIRE) -- New data from studies presented at the 2026 Alzheimer’s Association International Conference (AAIC) in London widened the gulf between science-backed brain...

Study at International Alzheimer's Conference Finds Brain Training Reduces Amyloid

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Austin, TX, USA, June 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Alzheimer’s Drug Market Size, Trends and Insights By Type of Drug...

Today's Marketplace interviews Acumen Pharmaceuticals CEO and Creighton University at the NASDAQ about targeted therapies for Alzheimer's.

ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...

AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...